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Abstract
Background: Radical prostatectomy is the most common treatment for localised prostate cancer in New Zealand.
Active surveillance was introduced to prevent overtreatment and reduce costs while preserving the option of radical
prostatectomy. This study aims to evaluate the cost-effectiveness of active surveillance compared to watchful waiting
and radical prostatectomy.
Methods: Markov models were constructed to estimate the life-time cost-effectiveness of active surveillance compared
to watchful waiting and radical prostatectomy for low risk localised prostate cancer patients aged 45–70 years, using
national datasets in New Zealand and published studies including the SPCG-4 study. This study was from the perspective
of the Ministry of Health in New Zealand.
Results: Radical prostatectomy is less costly than active surveillance in men aged 45–55 years with low risk localised
prostate cancer, but more costly for men aged 60–70 years. Scenario analyses demonstrated significant uncertainty as to
the most cost-effective option in all age groups because of the unavailability of good quality of life data for men under
active surveillance. Uncertainties around the likelihood of having radical prostatectomy when managed with
active surveillance also affect the cost-effectiveness of active surveillance against radical prostatectomy.
Conclusions: Active surveillance is less likely to be cost-effective compared to radical prostatectomy for younger men
diagnosed with low risk localised prostate cancer. The cost-effectiveness of active surveillance compared to radical
prostatectomy is critically dependent on the ‘trigger’ for radical prostatectomy and the quality of life in men on active
surveillance. Research on the latter would be beneficial.
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Background
Radical prostatectomy is the most common treatment
for patients diagnosed with localised prostate cancer in
New Zealand, [1] though it may cause urinary, sexual
and gastrointestinal problems [2]. Active surveillance is
considered to be a viable alternative for patients with
low risk localised prostate cancer, potentially preventing
overtreatment and reducing costs while preserving the
option of radical prostatectomy [3]. However, men under
active surveillance may suffer from physical complica-
tions due to the regular investigations such as biopsies,
and issues related to living with cancer, including anxiety
and depression [4, 5]. The cumulative risk of a radical
prostatectomy increases with time under surveillance.
Watchful waiting is mainly used in patients with a life
expectancy less than 10 years, but it was included in two
randomised clinical trials to compare with radical pros-
tatectomy [6, 7]. The Scandinavian Prostate Cancer
Group Study Number 4 (SPCG-4) showed that men
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treated with radical prostatectomy had fewer local pro-
gression cases, metastatic diseases and cancer-specific
deaths than men under watchful waiting after 18 years
of follow-up [6]. The Prostate Cancer Intervention ver-
sus Observation Trial (PIVOT) found no survival differ-
ence between the radical prostatectomy group and the
observation group [7]. The inconsistent results between
the SPCG-4 study and the PIVOT study might be associ-
ated with the different studied cohorts and follow-up
time: 5% vs 76% of men identified by screening; 36% vs
43% had low risk cancer; the mean age of 65 years vs
67 years; 45% vs 5% had 15 years follow-up [6–9].
No randomised clinical trial with a follow-up over
10 years has been conducted comparing active surveil-
lance and radical prostatectomy. Two published cost-
effectiveness studies [10, 11] comparing active surveillance
and radical prostatectomy were based on the PIVOT study
[7] where most patients were identified by screening. Given
the contradictive evidences of benefits and cost-
effectiveness of prostate cancer screening [12–16], a new
cost-effectiveness study of active surveillance is needed
using data of patients identified clinically. The New Zealand
Ministry of Health published guidelines on using active sur-
veillance to manage men with low risk prostate cancer in
July 2015 [3]. This study aims to evaluate the cost-
effectiveness of active surveillance compared to watchful
waiting and radical prostatectomy for men diagnosed with
low risk localised prostate cancer in New Zealand.
Methods
Ethics
This study was approved by Northern Y (Ref. No.
NTY/11/02/019) and Multi-Region Ethics Committees
(Ref. No. MEC/11/EXP/044). No inform consent is
required for this study.
Model construction
An economic model was constructed, consisting of
three Markov models with microsimulation (radical
prostatectomy (Additional file 1: Figure S1), active
surveillance (Fig. 1) and watchful waiting (Additional
file 1: Figure S2)). The cycle length was 1 year per
cycle [17]. The model populations were men diag-
nosed with low risk localised prostate cancer by the
D’Amico risk classification system (biopsy Gleason
score ≤ 6, clinical stage T1c-T2a and Prostate-specific
antigen (PSA) level ≤ 10 ng/mL) at the ages of 45,
50, 55, 60, 65 and 70 years. The simulations ended
when the cohort reached the age of 100.
The health states included ‘Localised’, ‘Post-surgery’,
‘Local progression’, ‘Metastatic’, ‘Death from prostate can-
cer’ and ‘Death from other causes’ (Fig. 1). In the SPCG-4
study, [6] some men diagnosed with localised prostate
cancer in both treatment arms developed metastatic dis-
ease in the first year. Therefore, we assumed some meta-
static cases were developed directly from ‘Localised’ or
‘Post-surgery’ states. In the active surveillance arm, pa-
tients would switch to watchful waiting once they reached
75 years old. When under 75 years old, 95% of them who
developed high risk cancer were assumed to be captured
and receive radical prostatectomy, and 5% of men were
assumed to develop to local progression.
Transition probabilities
The transition probabilities to ‘Local progression’ from
‘Post-surgery’ in the radical prostatectomy arm (Additional
Fig. 1 Influence diagram of the Markov model for active surveillance
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file 1: Figure S3) and from ‘Localised’ in the watchful wait-
ing arm were based on the SPCG-4 study published in
2008 [18]. The transition probabilities to metastatic disease
were estimated from the results of the SPCG-4 study pub-
lished in 2008 and in 2014 [6, 18]. The probability of death
from metastatic prostate cancer was estimated based on
276 patients [19–21]. The summarised annual transition
probabilities are shown in Table 1.
The probabilities of progression were estimated from a
cohort of men with localised prostate cancer. The
relative risks of these transition probabilities for low risk,
intermediate risk and high risk cancer (Table 2) com-
pared to the localised cancer cohort were estimated
based on the proportions of each risk level cancers in
the SPCG-4 cohorts [6, 18] and the relative risks of
biochemical recurrence for each risk level cancers [22].
They were estimated by dividing the possibilities of
biochemical recurrence for low, intermediate and high
risk cancer with the overall possibilities in the two arms
in the SPCG-4 study, respectively. The calculation was
repeated 100,000 times and Gamma distribution fit the
result distribution. The annual likelihood of having
radical prostatectomy in the active surveillance arm was
assumed to be equal to the transition probability from
low risk localised prostate cancer to ‘Local progression’
in the watchful waiting group, and that was 1.6%:
TP_Local-to-Localprogression_WW (Table 1) × RR_low-
risk_WW (Table 2).
Quality of life
The quality of life data in this model are presented in
Table 3. The only quality of life data that specifically
addressed active surveillance was from Stewart et al.
study [23] (mean value: 0.83). Half men included in that
study did not have prostate cancer when the study was
conducted. This quality of life value was only used in the
scenario analysis (please refer to scenario analyses).
The quality of life data for active surveillance used in
our model was based on a study conducted by Korfage
et al. [24]. A quality of life value of 0.89 for men before
radical prostatectomy was used as the quality of life for
men under active surveillance and a quality of life value
of 0.90 after radical prostatectomy was used as the qual-
ity of life for men after radical prostatectomy in this
model. Our Midland Prostate Cancer Study [21] esti-
mated a similar quality of life value (mean value: 0.88) in
42 men who were diagnosed with localised prostate
cancer and had radical prostatectomy.
A utility score of 0.820 for patients who received
external beam radiotherapy was used for the utility of
Table 1 Annual transition probabilities in the economic model
Transition probability Description Transition probabilities (Mean) SE Source
TP_Local-to-Localprogression_WW From Localised to Local
progression in the watchful
waiting arm
0.0565 0.0098 [18, 30]
TP_ Postsurgery-to-Localprogression_RP From Post-surgery to Local
progression in the radical
prostatectomy arm
0.0152+0.0012T (T: time (years)
from radical prostatectomy)
Additional file 1: Figure S3






TP_Local/Postsurgery-to-Metastatic From Localised or from
Post-surgery to metastases
0.0075 0.0010 [6, 30]
TP_Localprogression-to-Metastatic From Local progression
to metastases
0.0800 0.0050 [6, 30]
TP_DeathfromPC From Metastases to death
from prostate cancer
0.3221 0.0115 [19, 21]
TP_Deathfromothercauses Death from other causes New Zealand Period Life
Tables: 2010–12
- [31]
Table 2 Relative risks of cancer progression for low, intermediate
and high risk cancer compared to all localised prostate cancer
patients in the SPCG-4 study
Relative risk Risk group Mean SE Distribution
In the radical prostatectomy arm
RR_lowrisk_WW Low risk 0.2947 0.0100 Gamma
RR_intermrisk_WW Intermediate risk 1.0397 0.0347 Gamma
RR_highrisk_WW High risk 1.9600 0.0655 Gamma
In the watchful waiting arm
RR_lowrisk_RP Low risk 0.3006 0.0107 Gamma
RR_intermrisk_RP Intermediate risk 1.0606 0.0374 Gamma
RR_highrisk_RP High risk 1.9993 0.0703 Gamma
RR relative risk, RP radical prostatectomy, AS active surveillance, WW watchful
waiting RR_lowrisk_WW: relative risk of cancer progression for low risk patients
compared to localised prostate cancer patients in the watchful waiting arm
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patients with local progression, because patients diag-
nosed with locally advanced prostate cancer are mainly
treated with radiotherapy and hormone therapy.
Costs
This study was from the perspective of the Ministry of
Health in New Zealand, and only direct medical costs
were considered. The estimated costs excluded goods
and services tax (GST) and were valued in 2012/13 New
Zealand dollars (NZ$). A 3.5% discount rate was applied
to future costs and utilities.
The treatment costs (Table 4) were based on men
enrolled in the Midland Prostate Cancer Project and the
Metastatic Prostate Cancer Project [20, 21]. Patients
with local progression are treated with radiotherapy and
hormone therapy which is similar to the treatment
pattern for metastatic prostate cancer. The costs were
estimated from the National Non-Admitted Patient
Collection (NNPAC), National Minimum Dataset
(NMDS) and the Pharmaceutical Information Database
(PHARMS). These datasets can be linked through
patients’ National Health Index (NHI) numbers that is a
unique identifier that is assigned to people who use
health and disability support services in New Zealand.
NNPAC collects national records for outpatient and
emergency department events, NMDS contains clinical
data for inpatients and day patients, and PHARMS
includes all prescribed and dispensed records for subsi-
dised pharmaceuticals.
Cost-effectiveness analysis
The model construction and data analysis were
performed using TreeAge Pro 2015. The model used
an outer loop (n = 1000) to capture variation in
parameter values, with an inner loop microsimula-
tion considering outcomes for a simulated popula-
tion (n = 10,000). The costs and utilities for each
simulated man were calculated after each Markov
cycle by summing the costs and utilities attached to
the related health states and transitions in that cycle.
The life-time costs and QALYs (quality-adjusted life
years) per simulated man in each treatment arm
were estimated by averaging the total costs and util-
ities of all cycles and applying a half cycle correction
to all costs (except the costs of ‘Post-surgery’ in the
first year after radical prostatectomy) and utilities.
Uncertainty was assessed in all parameters using ap-
propriate distributions. The probability of progression
from ‘Post-surgery’ to ‘Local progression’ is based on
two parameters, so the Cholesky Decomposition is
Table 3 EQ-5D based quality of life results for patients at different health states
Health states Treatment Utility Disutility SE Sources
Post-surgery Radical prostatectomy 0.900 0.100 0.015 [24]
Localised prostate cancer Watchful waiting 0.890 0.110 0.013 [24]
Active surveillance 0.890 0.110 0.013 [24]
Local progression - 0.820 0.180 0.015 [24]
Metastatic prostate cancer: Not last year in life - 0.688 0.312 0.019 [32, 33]
Metastatic prostate cancer: final year of life - 0.551 0.449 0.060 [34]
Table 4 Costs of treatment for prostate cancer
Treatment Treatment year Age (Years) Mean SE Patients
Localised prostate cancer
Watchful waiting First year All $323 $193 27
Subsequent years All $0 $0 -
Active surveillance First year All $980 $676 25
Subsequent years <75 $812 $651 18
≥75 $0 $0 -
Radical prostatectomy First year All $13,527 $422 52
Subsequent years All $0 $0 -
Locally advanced and metastatic cancer
First year <80 $8,899 $711 145
Subsequent years <80 $6,573 $789 104
Not last year in life 80+ $3,887 $426 40
Last year in life 80+ $3,438 $502 75
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used. In all other cases, beta distributions were formed
for the other transition probabilities. Gamma distribu-
tions were similarly formed to model all disutilities (i.e.
the difference between 1 and the relevant utility) and
for all cost distributions.
Incremental analysis was performed in terms of in-
cremental cost-effectiveness ratio (ICER) by dividing
the incremental life-time costs with the incremental
life-time utilities. Cost-effectiveness acceptability
curves (CEAC) and frontier plots were also con-
structed to indicate the likelihood of each treatment
being cost-effective under a range of willingness-to-
pay values (the amount of money willing to pay for
a QALY gained) [25].
Scenario analyses
Five scenario analyses were conducted. The first scenario
analysis used an annual conversion rate of 5% from
active surveillance to radical prostatectomy. The 5%
conversion rate was used in the cost model built by
Corcoran et al. [26]. Hayes et al. used 0.83 (mean value)
as the quality of life after active surveillance and 0.80
(mean value) as the quality of life after treatment
without complications in their economic model [10, 27].
These quality of life values were used in the second sce-
nario analysis. The third scenario analysis used an alterna-
tive set of cost parameters (Additional file 1: Table S1),
which were based on the Waikato District Health Board
price list. The fourth scenario analysis used the quality of
life data in scenario two and the cost parameters in
scenario three. The fifth scenario analysis used all the data
in the first three scenarios.
Results
Cost-effectiveness analysis
Across all five age groups, men in the watchful waiting
arm had the lowest life-time costs but also the poorest
health outcomes in terms of both life years and QALYs
(Table 5). Expected life years were similar between the
active surveillance and radical prostatectomy arms, while
the number of QALYs was slightly lower for active sur-
veillance. The life-time costs of active surveillance were
higher than the costs of radical prostatectomy for men
diagnosed aged 45–50, but were lower than the costs of
radical prostatectomy for men diagnosed at higher ages.
For younger men (aged 45, 50 or 55 years), radical pros-
tatectomy appeared cost-effective compared to watchful
waiting with ICERs of NZ$6432 to NZ$10,358 per QALY
gained. Active surveillance was dominated (less effective
and more costly) by radical prostatectomy for men aged
40–50 and was extended dominated by watchful waiting
and radical prostatectomy for men aged 55.
For men aged 60, active surveillance was cost-effective
between willingness-to-pay values of around NZ$12,155–
21,485 per QALY. At an indicative figure of NZ$30,000
per QALY, radical prostatectomy appeared cost-effective.
However, for men aged 65 and 70, the ranges over which
active surveillance was cost-effective included this indica-
tive NZ$30,000 per QALY value (NZ$14,839–33,160 per
QALY and NZ$17,257–43,583 per QALY). At much lower
willingness-to-pay values (e.g. NZ$10,000 per QALY),
radical prostatectomy appeared cost-effective for the
youngest patients (aged 45 and 50).
The CEACs (Additional file 1: Figures S4 to S9) also
provided useful information as to which option is cost-
effective at different values of willingness-to-pay. These
Table 5 Cost per QALY gained for men with low risk localised prostate cancer
Age (years) Life-time outcome Watchful waiting Active surveillance Radical prostatectomy Incremental analysis
45 Cost (NZ$) $15,884 $23,396 $22,316 RP vs WW: $6,432 per QALY;
Effectiveness (QALYs) 15.43 16.34 16.43 AS was dominated by RP
50 Cost (NZ$) $14,192 $21,115 $20,991 RP vs WW: $7,906 per QALY;
Effectiveness (QALYs) 14.49 15.24 15.35 AS was dominated by RP
55 Cost (NZ$) $12,258 $18,484 $19,612 RP vs WW: $10,358 per QALY; AS was
extended dominated by WW and
RP (AS vs WW: $10,377 per QALY;
RP vs AS: $10,255 per QALY)
Effectiveness (QALYs) 13.37 13.97 14.08
60 Cost (NZ$) $10,113 $15,461 $18,254 AS vs WW: $12,155 per QALY;
Effectiveness (QALYs) 12.08 12.52 12.65 RP vs AS: $21,485 per QALY
65 Cost (NZ$) $7,843 $11,998 $16,972 AS vs WW: $14,839 per QALY;
Effectiveness (QALYs) 10.62 10.90 11.05 RP vs AS: $33,160 per QALY
70 Cost (NZ$) $5,560 $7,976 $15,821 AS vs WW: $17,257 per QALY;
Effectiveness (QALYs) 9.03 9.17 9.35 RP vs AS: $43,583 per QALY
RP radical prostatectomy, AS active surveillance, WW watchful waiting
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figures also highlighted that there remained significant
uncertainty as to the choice of the most cost-effective
option. In all the models up to 60 years of age, there
remained at least 30% likelihood that active surveillance
was the most cost-effective option at a figure of
NZ$30,000 per QALY. Whilst the possibility of radical
prostatectomy being cost-effective increased as higher
the willingness-to-pay values rise, this option was no
more than 65% likely to be cost-effective in any model
even at an unrealistic willingness-to-pay of NZ$100,000
per QALY.
Scenario analyses
The results of five scenario analyses are presented in
Table 6. When using the 5% conversion rate (scenario
one), the life-time cost of active surveillance increased
by 20–36% (aged 70), and the costs of active surveillance
were higher than the costs of radical prostatectomy for
men aged 45–60 (Additional file 1: Table S2). When
using the new quality of life values, the number of
QALYs in the active surveillance arm was higher than
that in the radical prostatectomy arm in all age groups,
and radical prostatectomy was either dominated by ac-
tive surveillance or extended dominated by active sur-
veillance and watchful waiting. When using new quality
of life values, costing values and the 5% conversion rate
(scenario five), the ICER of active surveillance compared
to watchful waiting increased to NZ$44,090–101,360 per
QALY gained. The new costing values (scenario three
and four) did not have substantial impact on the results.
Discussion
Men in the watchful waiting arm had the lowest life-
time costs but also the poorest health outcomes in terms
of both life years and QALYs. The model in this study
yielded similar numbers of life-years between the active
surveillance arm and the radical prostatectomy arm,
which was consistent with the evidence that active sur-
veillance and radical prostatectomy have similar effects
on the survival of men with low risk localised prostate
cancer [3, 28].
The life-time costs of active surveillance were lower
than the costs of radical prostatectomy for older men,
but were higher for younger men. This likely reflects the
fact that the longer a person under active surveillance,
the greater the risk of ultimately progressing to surgery
and the higher costs. In older men the chance of having
surgery is smaller, and active surveillance is a more ap-
propriate tool for them. The cost-effectiveness of active
surveillance was dependent on the quality of life for men
with localised prostate cancer under different treatment
options, and the annual probability of having radical
prostatectomy in the active surveillance arm.
The triggers of active treatment in the active surveil-
lance arm remain uncertain and different institutions
have their own protocols for both biopsy follow-up and
defining need to change from active surveillance to rad-
ical prostatectomy [29]. Whether or not these reflected
existing protocols, a systematic review including data
from seven large active surveillance studies reported that
up to one-third of men under active surveillance
received definitive treatment after a median follow-up of
2.5 years [28]. It was reported that 27–100% men were
treated because of histologic reclassification and 13–48%
due to PSA doubling time being less than 3 years,
while 7–13% of men were treated without evidence of
progression [28].
The model in this study assumed active treatment is
triggered only when histological progression of the local-
ised prostate cancer is detected, and an annual conver-
sion rate of 1.6% from active surveillance to radical
prostatectomy was used. With an annual conversion rate
of 1.6%, life-time costs of active surveillance were lower
than the costs of radical prostatectomy for men aged
55–70. This conversion rate is ideal rather than realistic
under current practice models.
The cost savings for active surveillance existed because
radical prostatectomy either does not occur or is likely
to occur a significant time into the future. With higher
annual conversion rates, prostatectomies become more
likely to occur and to occur sooner. The current surveil-
lance costs incurred can outweigh what is saved by
pushing the cost of potential prostatectomies into the
future, and in this case the life-time costs of active sur-
veillance can outweigh those of a radical prostatectomy.
When using the 5% conversion rate, the life-time costs
of active surveillance were higher than the costs of
radical prostatectomy for men aged 45–60. A study con-
ducted by Hayes et al. [10] showed that the life-time
costs of active surveillance were higher than the costs of
radical prostatectomy in men aged 65, using a 9% annual
rate of conversion. In reality, the annual probability of
converting from active surveillance to active treatment
might be over 10% [28].
Quality of life data for men under active surveillance
and that for men who received radical prostatectomy
appeared critical for the cost-effectiveness of active sur-
veillance compared to radical prostatectomy. Unfortu-
nately, there are no good quality of life data for men
under active surveillance. Our Midland Prostate Cancer
Study [21] had quality of life data on 42 men with rad-
ical prostatectomy (average quality of life:0.88, which is
close to the value used in the model) but only 3 men
with active surveillance. If the quality of life for men
under active surveillance is better than that in the rad-
ical prostatectomy arm and men in the active surveil-
lance arm would have radical prostatectomy only when
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high risk cancer was detected, active surveillance might
be cost-effective for men at all age groups. Otherwise it
might be only cost-effective for older patients.
One of the strengths of this study is that it synthe-
sized data from internationally recognised studies
and local costing and outcome data to provide rele-
vant economic information for decision making in
New Zealand. This model was based on data of
patients mainly identified clinically instead of by
screening, which is different from other cost-
effectiveness studies. Variations in different age groups
were taken into account, which was an advantage com-
pared to other published studies [10, 11, 26]. The entry
criteria for active surveillance in the New Zealand
guidelines [3] included a life expectancy of greater
than 10 years, but patient’s age was not mentioned.
Table 6 Scenario analysis for men with low risk localised prostate cancer
Age at diagnosis (Years) ICER (Cost per QALY gained) Dominance
AS vs WW RP vs WW AS vs RP RP vs AS
Scenario one: using the 5% conversion rate
45 - $6,441 - - AS was dominated by RP
50 - $7,908 - - AS was dominated by RP
55 - $10,361 - - AS was dominated by RP
60 - $14,021 - - AS was dominated by RP
65 - $21,226 - - AS was extended dominated by WW and RP
70 $31,135 - - $33,140 -
Scenario two: using new quality of life inputs
45 $11,060 - - - RP was extended dominated by WW and AS
50 $12,602 - - - RP was extended dominated by WW and AS
55 $14,814 - - - RP was dominated by AS
60 $17,807 - - - RP was dominated by AS and by WW
65 $21,916 - - - RP was dominated by AS and by WW
70 $26,833 - - - RP was dominated by AS and by WW
Scenario three: using new costing inputs
45 - $5,324 - - AS was dominated by RP
50 - $6,613 - - AS was dominated by RP
55 - $8,793 - - AS was dominated by RP
60 - $12,332 - - AS was extended dominated by WW and RP
65 $15,732 - - $24,000 -
70 $19,364 - - $35,761 -
Scenario four: using new quality of life inputs and costing inputs
45 $11,254 - - - RP was extended dominated by WW and AS
50 $12,882 - - - RP was extended dominated by WW and AS
55 $15,248 - - - RP was extended dominated by WW and AS
60 $18,520 - - - RP was dominated by AS and by WW
65 $23,184 - - - RP was dominated by AS and by WW
70 $30,122 - - - RP was dominated by AS and by WW
Scenario five: using new quality of life values, costing values and the 5% conversion rate
45 $22,904 - - - RP was extended dominated by WW and AS
50 $27,385 - - - RP was extended dominated by WW and AS
55 $33,790 - - - RP was extended dominated by WW and AS
60 $44,090 - - - RP was dominated by WW
65 $59,769 - - - RP was dominated by WW and by AS
70 $101,360 - - - RP was dominated by WW and by AS
RP radical prostatectomy, AS active surveillance, WW watchful waiting
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The results of this study might have some impact on
these guidelines.
This study has some limitations, including the uncer-
tainties on quality of life for men under active surveil-
lance. The quality of life for men at different ages was
assumed to be the same if they had identical treatment.
In reality, the quality of life may vary by age even under
the same treatment. GP costs were not considered in
this study. On average the number of PSA tests per
prostate cancer patient per year ordered by GPs was
only one, which implied that GPs do not play an import-
ant role in the on-going management of prostate cancer
patients. The model inputs included the costs of short-
term complications (included in the first year costs)
caused by radical prostatectomy but not the costs of
long-term complications. The long-term complications
are mainly managed by GPs, and most of the costs are
borne by patients and thus were not considered from
the perspective of the Ministry of Health. In the active
surveillance arm, radical prostatectomy was assumed to
be used when cancer progression was detected. Not
taking radiation treatment as definitive treatment into
account is a limitation of this study.
Conclusion
Active surveillance is less likely to be cost-effective com-
pared to radical prostatectomy for younger men diag-
nosed with low risk localised prostate cancer. The cost-
effectiveness of active surveillance compared to radical
prostatectomy is critically dependent on the ‘trigger’ for
radical prostatectomy and the quality of life in men on
active surveillance.
Early or unnecessary trigger of active treatment re-
duces the cost-effectiveness of active surveillance. If the
quality of life for men under observational management
was better than that for men having radical prostatec-
tomy, active surveillance was cost-effective compared
to radical prostatectomy, but was not cost-effective
compared to watchful waiting for older men with a
high annual probability of having radical prostatectomy
in the active surveillance arm. More research on these
specific points may allow a greater certainty when iden-
tifying the optimal management for men with low risk
prostate cancer.
Additional file
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